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Introduction
Epidemiological studies have shown a positive relationship between long-term stress and the development 
of  cardiovascular disease (1). Factors like social isolation, low socioeconomic status, depression, stressful 
family and work life, and anxiety are associated with an increased risk of  the development and accelerated 
progression of  existing cardiovascular disease. Current European guidelines on the prevention of  car-
diovascular disease have emphasized the importance of  tackling these factors (2). Mental stress induces 
myocardial ischaemia in patients with stable coronary artery disease, and this appears to be mediated by 
adrenal release of  catecholamines (3).
Cannabinoids (CBs) are compounds that bind to CB receptors or are structurally similar to com-
pounds that bind to CB receptors. They include endogenously produced compounds (called endocanna-
binoids), synthetic compounds and phytocannabinoids obtained from the Cannabis sativa plant. There are 
over 80 known types of  phytocannabinoids, the most widely studied of  which is Δ9 tetrahydrocannabinol 
(Δ9-THC or THC), which is responsible for the psychoactive properties of  cannabis (4). The other major 
phytocannabinoid is cannabidiol (CBD), which does not have psychoactive properties. CBD is currently 
the focus of  much research due to its potential in a number of  therapeutic areas, as it has been shown to 
have antiinflammatory, anticonvulsant, antioxidant, anxiolytic, antinausea, and antipsychotic properties 
(5). A number of  preclinical studies have also shown beneficial effects of  CBD in a range of  disorders of  
the cardiovascular system (6). A CBD/THC combination (Sativex/Nabiximols, GW Pharmaceuticals) 
is licensed for the treatment of  spasticity in multiple sclerosis, and CBD alone (Epidiolex, GW Phar-
maceuticals) has entered an expanded access program in children with intractable epilepsies (Dravet 
BACKGROUND. Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid used in multiple sclerosis 
and intractable epilepsies. Preclinical studies show CBD has numerous cardiovascular benefits, 
including a reduced blood pressure (BP) response to stress. The aim of this study was to investigate 
if CBD reduces BP in humans.
METHODS. Nine healthy male volunteers were given 600 mg of CBD or placebo in a randomized, 
placebo-controlled, double-blind, crossover study. Cardiovascular parameters were monitored using 
a finometer and laser Doppler.
RESULTS. CBD reduced resting systolic BP (–6 mmHg; P < 0.05) and stroke volume (–8 ml; P < 
0.05), with increased heart rate (HR) and maintained cardiac output. Subjects who had taken CBD 
had lower BP (–5 mmHg; P < 0.05, especially before and after stress), increased HR (+10 bpm; P < 
0.01), decreased stroke volume (–13 ml; P < 0.01), and a blunted forearm skin blood flow response 
to isometric exercise. In response to cold stress, subjects who had taken CBD had blunted BP (–6 
mmHg; P < 0.01) and increased HR (+7 bpm; P < 0.05), with lower total peripheral resistance.
CONCLUSIONS. This data shows that acute administration of CBD reduces resting BP and the BP 
increase to stress in humans, associated with increased HR. These hemodynamic changes should 
be considered for people taking CBD. Further research is required to establish whether CBD has a 
role in the treatment of cardiovascular disorders.
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syndrome and Lennox-Gastaut syndrome). Epidiolex has also received orphan designation status for the 
treatment of  neonatal hypoxia-ischaemic encephalopathy.
CBD has multiple desirable effects on the cardiovascular system. It attenuates high glucose–
induced proinflammatory changes in human coronary artery endothelial cells (7) and myocardial dys-
function associated with animal models of  diabetes (8), and it preserves endothelial integrity in diabet-
ic retinal microvasculature (9). In vivo administration of  CBD before cardiac ischemia and reperfusion 
also reduces ventricular arrhythmias and infarct size. CBD also causes both acute and time-dependent 
vasorelaxation in isolated arteries in rats and humans (10–12). There is also evidence from animal 
studies that CBD modulates the cardiovascular response to stress. Resstel and colleagues (13) showed 
in rats that i.p. injection of  CBD (10 and 20 mg/kg, –30 min) reduced restraint stress–induced cardio-
vascular response and behavior. Both these effects were blocked by preadministration of  WAY100635 
(0.1 mg/kg), a 5-hydroxytryptamine 1A (5HT1A) antagonist. These effects appear to be mediated cen-
trally and involve the bed nucleus of  the stria terminalis (BNST), a limbic structure that modulates 
neuroendocrine responses to acute stress (14).
Our recent systematic review showed us that there are no dedicated studies in humans to date, to our 
knowledge, looking at the effect of  CBD on either resting cardiovascular measurement or on the responses 
to stress, with continuous monitoring of  CV parameters (15). Therefore, the aim of  the present study was to 
investigate whether CBD decreases the cardiovascular response to stress after the administration of  a single 
dose of  CBD (600 mg) in healthy volunteers, with the hypothesis that blood pressure would be reduced by 
CBD. Noninvasive cardiovascular measurements were used along with stress tests in the form of  mental 
arithmetic, isometric exercise, and the cold pressor test.
Figure 1. Changes in resting cardiovascular parameters after a single dose (600 mg) of cannabidiol (CBD) in healthy volunteers (n = 9). The effects of 
placebo (closed square) and CBD (open square) on systolic blood pressure (SBP) (A), diastolic blood pressure (DBP) (B), mean arterial blood pressure (MAP) 
(C), heart rate (HR) (D), stroke volume (SV) (E), cardiac output (CO) (F), ejection time (EJT) (G), total peripheral resistance (TPR) (H), and forearm blood flow 
(I), measured continuously over 2 hours after drug ingestion, except for forearm blood flow. Forearm blood was measured over a time period of 2 minutes 
just before the start and in between the stress tests. Dotted line denotes baseline values between the stress tests. Repeated measures 2-way ANOVA; 
mean ± SEM (*/+/#P < 0.05, **/++/##P < 0.01 using Bonferroni’s post-hoc analysis; + and # represent significant change in any parameter over time seen 
with placebo and CBD, respectively; denotes overall significant difference between 2 treatments).
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Results
Ten male subjects were recruited, but 1 withdrew for personal reasons. The mean age, weight, and 
height of  the volunteers were 23.7 ± 3.2 years, 77.5 ± 6.4 kg, and 178.6 ± 4.5 cm (mean ± SD).
Effect of  CBD on resting cardiovascular parameters. CBD treatment reduced resting systolic blood pressure 
Figure 2. Individual systolic and diastolic blood pressure responses to all stress tests after a single dose (600 mg) of cannabidiol (CBD) or placebo in 
healthy volunteers (n = 9). Green color coding shows subjectS who had a reduced (compared with placebo) blood pressure response to stress after taking 
CBD, and red color coding shows an increased blood pressure response to stress after taking CBD.
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(SBP) (mean difference –6 mmHg; 95% CI, –1 to –12, P < 0.05, Figure 1A). Although there was no overall 
difference in diastolic blood pressure (DBP) and mean arterial blood pressure (MAP) between the 2 groups, 
post-hoc analysis showed that both DBP and MAP were lower with CBD treatment (Figure 1, B and C, 
respectively; P < 0.01), particularly in the latter time points (120–160 min).
CBD treatment reduced resting stroke volume (SV; mean difference –8 ml; 95% CI, –2 to –14, P < 0.05, 
Figure 1E) and increased heart rate (HR), with significant difference in HR between CBD and placebo from 
an hour after ingestion of  drug (Figure 1D, P < 0.05). There was a decline in left ventricular ejection time (EJT) 
with both treatments (P < 0.05; Figure 1G), while cardiac output (CO) (Figure 1F) remained unchanged.
There was a trend toward reduction in total peripheral resistance (TPR, Figure 1H) with CBD in the 
latter half  of  the resting period, and a significant reduction in forearm skin blood flow before the start of  
the stress tests (Figure 1I; P < 0.01).
Effect of  CBD on cardiovascular parameters mental stress. The individual blood pressure responses of  healthy 
volunteers to the stresses are presented in Figure 2, showing the average baseline systolic or diastolic blood 
pressure in the 4 minutes preceeding the stress test, the peak response during stress, and the average recov-
ery response in the 4 minutes after the stress test.
Mental stress test. Mental stress caused a rise in HR (P < 0.05; Figure 3D) and a decline in SV (P < 0.01; 
Figure 3E), which was seen in both the CBD and placebo groups. There was a rise in DBP (P < 0.05; Figure 
3B) and a decline in EJT (P < 0.05; Figure 3G), seen only in those who had taken CBD.
Figure 3. Cardiovascular response to mental stress after a single dose (600 mg) of cannabidiol (CBD) in healthy volunteers (n = 9). The effects of placebo 
(closed square) and CBD (open square) on systolic blood pressure (SBP) (A), diastolic blood pressure (DBP) (B), mean arterial blood pressure (MAP) (C), heart 
rate (HR) (D), stroke volume (SV) (E), cardiac output (CO) (F), ejection time (EJT) (G), total peripheral resistance (TPR) (H), and forearm blood flow (I), mea-
sured continuously just before, during, and after mental arithmetic test (dotted line denotes stress test period), except for forearm blood flow. Measure-
ments for forearm blood flow were made over a 2-minute window just before, during, and after the stress test. Repeated measures 2-way ANOVA; mean ± 
SEM (+ and # denote significant change in a parameter during the stress period seen with placebo and CBD, respectively). +/#P < 0.05, ++/##P < 0.01.
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Although overall, there was no difference in the cardiovascular parameters between the 2 treatments, 
post-hoc analysis showed that SBP (Figure 3A; P < 0.05 to < 0.0001), DBP (Figure 3B; P < 0.05 to < 0.01), 
and MAP (Figure 3C; P < 0.05 to < 0.0001) were significantly lower in volunteers who had taken CBD, 
especially immediately after the stress test. Looking at the individual response to mental stress, 6 of  9 
subjects had a lower SBP before or during the mental stress test, and 9 of  9 subject had a lower SBP in the 
recovery period after taking CBD (Figure 2). Five of  9 subjects had a lower DBP during the mental stress 
test, and 6 of  9 subject had a lower DBP in the recovery period after taking CBD (Figure 2).
CBD increased HR during the latter part of  mental stress and in the poststress period (Figure 3D; P < 0.05 
to < 0.0001), with a corresponding decline in EJT (Figure 3G; P < 0.05 to < 0.0001). Although CBD reduced 
SV (Figure 3E; P < 0.05 to < 0.0001), there was no difference in CO between CBD and placebo (Figure 3F).
Compared with placebo, volunteers who had taken CBD had a lower TPR throughout and especial-
ly in the post–mental stress period (Figure 3H; P < 0.05 to < 0.0001). Volunteers who had taken CBD 
also reduced forearm skin blood flow before and during the latter part of  mental stress (Figure 3I; P < 
0.05 to < 0.01).
Exercise stress test. The isometric exercise stress caused a significant rise in the following parameters in 
both treatment groups; SBP (placebo P < 0.01, CBD P < 0.001; Figure 4A), DBP (placebo P < 0.01, CBD 
P < 0.0001; Figure 4B), MAP (placebo P < 0.01, CBD P < 0.0001; Figure 4C), and HR (placebo P < 0.05, 
CBD P < 0.001; Figure 4D).
Figure 4. Cardiovascular parameters in response to exercise stress after a single dose (600 mg) of cannabidiol (CBD) in healthy volunteers (n = 9). The 
effects of placebo (closed square) and CBD (open square) on systolic blood pressure (SBP) (A), diastolic blood pressure (DBP) (B), mean arterial blood pres-
sure (MAP) (C), heart rate (HR) (D), stroke volume (SV) (E), cardiac output (CO) (F), ejection time (EJT) (G), total peripheral resistance (TPR) (H), and forearm 
blood flow (I), measured continuously just before, during, and after isometric exercise test (dotted line denotes stress test period), except for forearm blood 
flow. Measurements for forearm blood flow were made over a 2-minute window just before, during, and after the stress test. Repeated measures 2-way 
ANOVA; mean ± SEM (*/+/#P < 0.05; **/++/##P < 0.01; ***/###P < 0.001; ****/####P < 0.0001 using Bonferroni post-hoc analysis; + and # denote significant 
change in a parameter during the stress period seen with placebo and CBD respectively).
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Overall, CBD treatment reduced SBP (mean difference –5 mmHg; 95% CI, –1 to –10, P < 0.05, Figure 4A) 
and MAP (mean difference –5 mmHg, 95% CI, –2 to –9, P < 0.05, Figure 4C) during the exercise stress. Look-
ing at the individual response to exercise stress, 6 of 9 subjects had a lower SBP during isometric exercise and 8 
of 9 subjects had a lower SBP in the recovery period after taking CBD (Figure 2). Five of 9 subjects had a lower 
DBP during exercise, and 8 of 9 subject had a lower DBP in the recovery period after taking CBD (Figure 2).
Subjects who had taken CBD had increased HR (mean difference 10 bpm; 95% CI, 5–14, P < 0.01, 
Figure 4D) and decreased SV (mean difference –13 ml; 95% CI, –4 to –22, P < 0.01, Figure 4E) and EJT 
(mean difference –0.01 sec, 95% CI, –0.001 to –0.03, P < 0.05, Figure 4G) during the exercise stress. There 
was no difference in CO during the exercise stress (Figure 4F).
A rise in forearm cutaneous blood flow in response to exercise (as would be expected) was only seen 
in volunteers who had taken placebo (P < 0.05; Figure 4I). Post-hoc analysis showed significantly lower 
forearm skin blood flow in those who had taken CBD (Figure 4I; P < 0.001 to < 0.0001), during the early 
and latter parts of  the stress test. This was associated with reduced TPR (Figure 4H; P < 0.05 to < 0.001) 
before, after, and in the latter half  of  exercise stress.
Cold stress test. The cold pressor test caused a rise in SBP (placebo P < 0.01, CBD P < 0.05; Figure 5A) 
and MAP (placebo P < 0.001, CBD P < 0.05; Figure 5C) in both groups and a rise in DBP only with place-
bo (P < 0.01; Figure 5B). An equal rise in SBP and MAP was seen with both CBD and placebo in the first 
half  of  this stress test. However, while the blood pressure (SBP and MAP) continued to rise in the placebo 
group, it plateaued in volunteers who had taken CBD, and therefore both SBP and MAP were significantly 
Figure 5. Cardiovascular response to cold stress after a single dose (600 mg) of cannabidiol (CBD) in healthy volunteers (n = 9). The effects of placebo 
(closed square) and CBD (open square) on systolic blood pressure (SBP) (A), diastolic blood pressure (DBP) (B), mean arterial blood pressure (MAP) (C), heart 
rate (HR) (D), stroke volume (SV) (E), cardiac output (CO) (F), ejection time (EJT) (G), total peripheral resistance (TPR) (H), and forearm blood flow (I), measured 
continuously just before, during, and after cold pressor test (dotted line denotes stress test period), except for forearm blood flow. Measurements for forearm 
blood flow were made over a 2-minute window just before, during, and after the stress test. Repeated measures 2-way ANOVA; mean ± SEM (*/+/#P < 0.05, 
**/++P < 0.01, ***/+++P < 0.001, ****P < 0.0001 using Bonferroni post-hoc analysis; + and # denote significant change in a parameter during the stress period 
seen with placebo and CBD, respectively).
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lower in volunteers after CBD (mean difference –8 mmHg [95% CI, –4 to –12, P < 0.01] and –6 mmHg 
[95% CI, –2 to –11, P < 0.01]). Post-hoc analysis showed that DBP was also significantly lower in those 
who had taken CBD in the latter half  of  the stress period (Figure 5B; P < 0.001).
Looking at the individual response to the cold pressor test, 8 of  9 subjects had a lower SBP during the 
cold stress and in the recovery period after taking CBD (Figure 2). Six of  9 subjects had a lower DBP during 
the cold pressor, and 7 of  9 subject had a lower DBP in the recovery period after taking CBD (Figure 2).
As before, HR was higher in volunteers who had taken CBD (mean difference 7 bpm; 95% CI: 2–13; 
P < 0.05; Figure 5D), and EJT was lower (mean difference -0.01 sec; 95% CI: 0 to –0.02; P < 0.05; Figure 
5G). Sidak post-hoc analysis showed that SV was significantly lower with CBD throughout (Figure 5E; P < 
0.05 to < 0.0001), but there was no decline in cardiac output (Figure 5F).
The cold pressor test caused a significant rise in TPR (as expected) in the placebo group only (Figure 
5H; P < 0.01) and rise in forearm skin blood flow with both CBD and placebo (Figure 5I; P < 0.05). The 
overall trend was for lower TPR and forearm skin blood flow in those who had taken CBD, with post-hoc 
analysis showing a reduction in both just before and in the latter half  of  cold stress (Figure 5H [P < 0.05 to 
< 0.0001] and Figure 5I [P < 0.001]).
Discussion
Based on preclinical evidence, the aim of  this study was to test the hypothesis that CBD would reduce the 
cardiovascular response to stress in healthy volunteers. We found that resting blood pressure was lower after 
subjects had taken CBD and that CBD blunted the blood pressure response to stress, particularly in the 
pre- and poststress periods. Post-hoc analysis showed an overall trend of  lower SBP, MAP, DBP, SV, TPR, 
forearm skin blood flow, and left ventricular EJT and a higher HR in subjects who had taken CBD. These 
hemodynamic changes should be considered for people taking CBD and suggest that further research is 
warranted to establish whether CBD has any role in the treatment of  cardiovascular disorders.
We have shown for the first time that to our knowledge that, in humans, acute administration of  CBD 
reduces resting blood pressure, with a lower stroke volume and a higher heart rate. This response may be 
secondary to the known anxiolytic properties of  CBD (16) and may account for the lack of  anticipatory 
rise in blood pressure seen with placebo. These findings are in contrast to previous studies in humans, 
where CBD at the same dose did not affect baseline cardiovascular parameters (17–19), although changes 
in the cardiovascular system were not the primary outcome of  these studies. In the present study, CV 
parameters were measured continuously, while in previous studies, monitoring for SBP, DBP, and HR 
were performed manually at only 1, 2, or 3 hours after drug delivery. Additionally, our subjects were can-
nabis naive, while the subjects of  other studies had used cannabis in the past. Since tolerance may develop 
to the hemodynamic response to CBs in humans, this may explain the differences between studies.
THC, the major psychoactive component of  cannabis, is known to cause tachycardia and orthostatic 
hypotension in humans (20), a hemodynamic response similar to that observed to CBD in the present 
study. THC is a partial agonist at both CB1 and CB2 receptors (21), and the effects of  THC on heart rate 
are mediated through CB1 receptors (20). CBD does not bind with any great affinity to CB1, but it can inter-
act indirectly by augmenting CB1 receptors’ constitutional activity or endocannabinoid tone, the so called 
indirect agonism (22). We recently showed that CBD also causes endothelium-dependent vasorelaxation in 
isolated human mesenteric arteries through CB1 activation (11). Therefore, it is possible that the changes in 
hemodynamics brought about by CBD are mediated through CB1.
CBD may cause sympathoinhibition (through CB1 or some other mechanism), thereby preventing an 
increase in blood pressure and cardiac output, causing a compensatory rise in heart rate to maintain cardiac 
output. Indeed, the changes in SBP preceded any changes in HR. Another possibility is that CBD inhibits 
cardiac vagal tone, thereby increasing heart rate (despite any potential sympathoinhibition). A recent study 
in male Sprague-Dawley rats showed that GPR18 activation in the rostral ventrolateral medulla (RVLM) 
by abnormal CBD (Abn-CBD) resulted in reduced blood pressure and increased heart rate (23) (similar to 
that observed in the present study). The same study showed that pretreatment with atropine and propran-
olol fully abrogated the HR response, suggesting a role for the autonomic nervous system. CBD is a weak 
partial agonist at GPR18 (24).
Effect of  CBD on cardiovascular parameters in response to mental stress. Mental arithmetic has been 
shown to cause a rise in MAP and muscle sympathetic nerve activity (MSNA) (25) and vasodilatation 
in forearm skeletal muscle (26). In our study, none of  the cardiovascular parameters other than HR, 
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DBP, and SV were affected, suggesting that the level of  stress to this test was minimal. This could be 
because of  the added visual stimulus of  a computer screen, which would have helped volunteers per-
form the task. Overall, there was trend for lower SBP, DBP, MAP, SV, TPR, and forearm skin blood 
flow in subjects who had taken CBD, particularly in the pre– and post–stress test periods. Like resting 
cardiovascular parameters, these changes may indicate anxiolytic effects of  CBD and/or generalized 
sympathoinhibition.
Effect of  CBD on cardiovascular parameters in response to exercise stress. Isometric exercise produces a pres-
sor response, via sympathoexcitation, originating in the contracting muscle and relayed to the RVLM via 
the nucleus of  solitary tract. The end result is a rise in heart rate and cardiac output and vasoconstriction 
in nonexercising organs (27–29). There is increased skeletal muscle blood flow in the nonexercising limb, 
which is sensitive to atropine and propranolol (30). A similar response was seen in our study, where iso-
metric exercise caused a significant rise in SBP, DBP, MAP, and HR and an increase in forearm blood flow, 
although this was significant in the placebo group only. Subjects who had taken CBD had reduced blood 
pressure during the exercise stress test, and this was most pronounced in the pre- and posttest period. Before 
the exercise stress, HR was higher and SV lower in volunteers when they had taken CBD, and this trend 
continued throughout exercise stress and in the poststress period. There was also a significant reduction in 
EJT with CBD, which represents a reciprocal change to increased HR. The rise in cutaneous blood flow 
was only seen with placebo and not with CBD, possibly suggesting reduced β2 adrenergic–mediated vasodi-
latation, which could be a result of  general sympathoinhibition or a specific effect at the β2 adrenoceptors. 
The tissue distribution of  β2 adrenoceptors and CB1 receptors overlaps in many tissues, including in the 
cardiovascular system (31). At the cellular level, a complex physical and functional interaction between 
these 2 receptors has been demonstrated; there is evidence of  cointernalization of  β2 adrenoceptors with 
CB1 receptors, leading to desensitisation of  β2 adrenoceptors (31).
Effect of  CBD on cardiovascular parameters in response to cold stress. Cold stress causes intense sympatho-
excitation, producing a tachycardic and pressor response, and an increase in MSNA (32, 33). The pressor 
response is due to an initial rise in CO, in response to increased HR and a later increase in MSNA, causing 
vasoconstriction. Both MAP and TPR show a linear correlation with MSNA during cold stress (34). In our 
study, cold stress produced a pressor response in both groups, but, interestingly, while SBP and MAP con-
tinued to rise with placebo throughout the test period, the pressor response to cold was blunted in subjects 
who had taken CBD, and SBP and MAP were significantly lower. In keeping with this, TPR was lower 
with CBD than placebo, suggesting a possible inhibition of  sympathetic outflow. This could also be due to 
analgesic properties of  CBD (35), reducing cold stress and therefore minimizing the sympathetic response 
(also explaining why the cold pressor test was affected more by CBD than the exercise test). In the animal 
study of  Resstel and colleagues (13), the authors suggested that the modulation of  cardiovascular response 
was most likely secondary to attenuation of  emotional response to stress. However, given our findings that 
CBD produced similar changes in cardiovascular parameters — though to a variable degree — during rest 
and stress, this may indicate that CBD also has direct cardiovascular effects.
Safety and tolerance. CBD was well tolerated, and there were no adverse events on the day of  stress tests. 
None of  the subjects reported any adverse events over the following week.
Conclusion. Our data show that a single dose of  CBD reduces resting blood pressure and the blood 
pressure response to stress, particularly cold stress, and especially in the post-test periods. This may reflect 
the anxiolytic and analgesic effects of  CBD, as well as any potential direct cardiovascular effects. CBD 
also affected cardiac parameters but without affecting cardiac output. Giving the increasing use of  CBD 
as a medicinal product, these hemodynamic changes should be considered for people taking CBD. Further 
research is also required to establish whether CBD has any role in the treatment of  cardiovascular disorders 
such as a hypertension.
Methods
Study design. The study was a randomized, crossover design with each subject given CBD (BN: K12067A) 
or placebo (both gifts from GW Pharmaceuticals) in a capsule in a double-blind fashion, with a minimum 
time interval of  at least 48 hours (range 3–16 days), taking place at the Division of  Medical Sciences, 
School of  Medicine, Royal Derby Hospital. Allocation was decided by a coin toss, and block randomiza-
tion was employed by S.E. O’Sullivan, who assigned participants. K.A. Jadoon carried out all study visits, 
and data analysis was blinded.
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During an initial visit, subjects were familiarized with the stress tests and with noninvasive cardiovascu-
lar (CVS) monitoring, and an electrocardiogram (ECG) was done to rule out any preexisting cardiac con-
ditions. Subjects were advised to fast overnight, to avoid beverages containing caffeine or alcohol, and to 
avoid strenuous exercise for 24 hours before each of  the 2 study visits. Two hours after CBD/placebo was 
administered, subjects performed various stress tests (36). Noninvasive cardiovascular monitoring using 
Finometer and laser Doppler flowmetry was carried out during the 2 hours to assess changes in baseline 
parameters and during the stress test periods.
Visit days. Upon arrival, subjects were rested for 10–15 minutes, and their baseline blood pressure and 
heart rate were recorded using a digital blood pressure (BP) monitor. Participants were given a standardized 
breakfast, and 15 minutes later, they were given either oral CBD (600 mg) or placebo in a double-blind 
fashion. This is a dose known to cause anxiolytic effects in humans and is comparable with what is used 
clinically (19, 37–39). Study medication consisted of  capsules containing either 100 mg of  CBD or excipi-
ents, which were a gift from GW Pharmaceuticals. There was no difference between the 2 formulations in 
color, taste, or smell.
Two hours afterward, subjects were asked to perform the stress tests (36). Timing of  the tests was 
chosen to coincide with peak plasma levels for CBD (18). All the experiments were performed in a sitting 
position under ambient temperature conditions. Maximum voluntary contraction for the isometric hand 
grip test was assessed for each subject prior to administering study medication.
After administration of  CBD or placebo, subjects remained seated, either doing nothing, reading, 
or using a computer. During this time, subjects were connected to a calibrated Finometer (Finapres 
Medical Systems), which uses a finger-clamp method to detect beat-to-beat changes in digital arterial 
diameter using an infrared photoplethysmograph (40). The Finometer gives a continuous signal of  
beat-to-beat changes in blood pressure and blood flow, and it uses this signal to derive other parameters, 
including systolic, diastolic, and mean blood pressure; interbeat interval; heart rate and left ventricular 
ejection time; stroke volume; cardiac output; and systemic peripheral resistance. Baseline cardiovascu-
lar data was recorded for 2 hours following administration of  CBD or placebo. Forearm blood flow was 
measured using a calibrated laser Doppler flowmeter (Perimed) (41). For each recording, 5 images of  
microcirculation were taken, over an area 19 mm × 19 mm, using the upper third of  the left forearm 
under high resolution. After 2 hours, subjects underwent the cardiovascular stress tests in the following 
order: mental arithmetic, isometric exercise, and cold pressor test.
The mental arithmetic test consisted of  calculating a sum every 2 second for 2 minutes. Subjects were 
seated in front of  a computer screen, and a PowerPoint presentation delivered a slide with a simple mathe-
matical sum of  a 3-digit number minus a smaller number (e.g., 317 – 9, 212 – 11, 185 – 7) every 2 seconds; 
the subject had to give the answer verbally. In the isometric exercise stress test, using a dynamometer, hand-
grip was maintained at 30% of  maximum voluntary contraction (MVC) for 2 min. For the cold pressor test, 
subjects immersed their left foot (up to ankle) in ice slush (temperature 4°C–6°C) for 2 minutes. Cardiovas-
cular parameters were measured continuously using the Finometer, while skin blood flow measurements 
were taken just before, during, and 5 minutes after each test. Each stress test lasted for 2 minutes, and there 
was a recovery period of  at least 10 minutes.
Statistics. Data were analyzed using repeated measures ANOVA to determine the effect of  treat-
ment and time on different variables using GraphPad PRISM version 6.02. Level of  significance was 
set at α = 0.05 and values presented as mean ± SEM. Sidak’s post-hoc test was used to see treatment 
affect at various time points. Data were not unblinded until after statistical analysis.
Study approval. Ten healthy young male volunteers, mean age 24 years (range 19–29), with no under-
lying cardiovascular or metabolic disorders, were recruited for this study, which was approved by the 
University of  Nottingham Faculty of  Medicine Ethics Committee (study reference E18102012). Written 
informed consent was obtained according to the Declaration of  Helsinki. Exclusion criteria included 
any significant cardiovascular or metabolic disorder or use of  any medication. All the volunteers were 
nonsmokers and had taken no prescribed or over-the-counter medication within a week prior to random-
ization. No volunteers had ever used cannabis.
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